Heterogeneity of baseline neural marker expression by undifferentiated mesenchymal stem cells may be correlated to donor age.
Heng BC., Saxena P., Fussenegger M.
Laboratory Study, published in J Biotechnol (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Biotechnol (2014)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24486027
- DOI
- 10.1016/j.jbiotec.2014.01.021
Abstract (original English)
Previous studies reported much heterogeneity in baseline neural marker expression by undifferentiated mesenchymal stem cells (MSCs) of animal and human origin, which could confound reproducibility of neural differentiation experiments with MSCs. Nevertheless, basic donor characteristics such as age and gender were unspecified in these previous studies; and relative levels of baseline neural marker expression amongst primary MSCs of different tissue and donor origin have not been compared by quantitative real-time polymerase chain reaction (qRT-PCR) analysis, which is the focus of this study. The results showed that amongst a mixed group of primary adipose and bone marrow-derived MSCs (12-50 years), the observed variability in baseline neural marker expression may be correlated to donor age. Adipose-derived MSCs from the youngest donor (male, 12 years old) displayed the highest expression of all four early neural markers (Pax6, Nestin, Musashi 1 and βIII-tubulin), and three out of four mature neural markers (NCAM, NSE and NFM) analyzed by qRT-PCR. Conversely, adipose MSCs of the oldest donor (female, 50 years old) displayed the lowest expression of three out of four early neural markers (Pax6, Musashi 1 and βIII-tubulin), and three out of four mature neural markers (MAP2, NCAM and NSE) analyzed by qRT-PCR.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.